SCHEMBL23270615

SCHEMBL23270615

CCC1(O)C(=O)OCc2c1cc1n(c2=O)Cc2cc3c(O)cccc3nc2-1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TOP1 P11387 18/20 1.00
▸ ALDH1A1 P00352 3/20 1.00
▸ GLA P06280 3/20 1.00
▸ MEN1 O00255 3/20 1.00
▸ KMT2A Q03164 3/20 1.00
▸ SMN1; SMN2 Q16637 3/20 1.00
▸ RECQL P46063 2/20 1.00
▸ TDP1 Q9NUW8 2/20 1.00
▸ KDM4E B2RXH2 4/20 0.82
▸ RAB9A P51151 2/20 0.82
▸ BLM P54132 2/20 0.82
▸ MAPT P10636 2/20 0.82
▸ POLB P06746 1/20 0.82
▸ ABCC4 O15439 2/20 0.78
▸ HTT P42858 2/20 0.78
▸ ABCC3 O15438 1/20 0.78
▸ ACHE P22303 1/20 0.78
▸ PTGS1 P23219 1/20 0.78
▸ ABCC2 Q92887 1/20 0.78
▸ TP53 P04637 2/20 0.77

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29664993 1.00 TOP1 (1.00) TOP1ALDH1A1GLAMEN1KMT2A
SCHEMBL1301708 1.00 TOP1 (1.00) TOP1ALDH1A1GLAMEN1KMT2A
Camptothecin SCHEMBL29056181 0.96 TOP1 (0.92) TOP1ALDH1A1GLAMEN1KMT2A
SCHEMBL27561956 0.92 TOP1 (1.00) TOP1ALDH1A1GLAMEN1KMT2A
SCHEMBL1006662 0.92 TOP1 (1.00) TOP1ALDH1A1GLAMEN1KMT2A
SCHEMBL27489142 0.91 TOP1 (0.85) TOP1ALDH1A1GLAMEN1KMT2A
SCHEMBL3847426 0.91 TOP1 (0.85) TOP1ALDH1A1GLAMEN1KMT2A
SCHEMBL1062768 0.91 TOP1 (1.00) TOP1ALDH1A1GLAMEN1KMT2A
SCHEMBL27502037 0.91 TOP1 (1.00) TOP1ALDH1A1GLAMEN1KMT2A
SCHEMBL6848647 0.90 TOP1 (0.84) TOP1ALDH1A1GLAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210228530-A1 TAXANE-LIPID-POLYSACCHARIDE DUAL CONJUGATES, PREPARATION METHODS THEREOF AND USES THEREOF SANTOLECAN PHARMACEUTICALS LLC 2021-07-29 — — US claimed
EP-3812376-A1 PACLITAXEL-LIPID-POLYSACCHARIDE DUAL-TYPE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF Santolecan Pharmaceuticals LLC (US) 2021-04-28 — — EP claimed
CN-107303272-A A kind of nano-crystal composition for improving insoluble drug oral absorption 北京大学 2017-10-31 — — CN disclosed
CN-102172405-B Multi-arm polymer prodrugs NEKTAR THERAPEUTICS 2014-11-12 — — CN disclosed
CN-102159250-B Multi-arm polymeric alkanoate conjugates NEKTAR THERAPEUTICS 2014-08-06 — — CN disclosed
CN-101583380-B Method for preparing a polymer conjugate NEKTAR THERAPEUTICS AL CORP 2013-07-10 — — CN disclosed
CN-102172405-A Multi-arm polymer prodrugs NEKTAR THERAPEUTICS 2011-09-07 — — CN disclosed
CN-102164617-A Compositions and methods for achieving sustained therapeutic drug concentrations in a subject NEKTAR THERAPEUTICS 2011-08-24 — — CN disclosed
CN-102159250-A Multi-arm polymeric alkanoate conjugates NEKTAR THERAPEUTICS 2011-08-17 — — CN disclosed
CN-1852740-B Prodrugs of highly branched polymers NEKTAR THERAPEUTICS AL CORP 2011-05-11 — — CN disclosed
CN-101583380-A Method for preparing a polymer conjugate NEKTAR THERAPEUTICS AL CORP (US) 2009-11-18 — — CN disclosed
CN-1852740-A Prodrugs of highly branched polymers NEKTAR THERAPEUTICS AL CORP (US) 2006-10-25 — — CN disclosed
CN-1101818-C Novel water-soluble C-ring analogues of 20(s)-camptothecin REDDY RESEARCH FOUNDATION (IN) 2003-02-19 — — CN disclosed
CN-1198164-A Novel water-soluble C-ring analogues of 20 -camptothecin REDDY RESEARCH FOUNDATION (IN) 1998-11-04 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210228530-A1 TAXANE-LIPID-POLYSACCHARIDE DUAL CONJUGATES, PREPARATION METHODS THEREOF AND USES THEREOF DDOST, UGT2B17, UGT1A7 TOP1 54/4885ALDH1A1 345/4885GLA 1145/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback